Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by equities researchers at Mizuho from $144.00 to $150.00 in a report issued on Tuesday. The firm currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Mizuho’s target price would suggest a potential upside of 12.23% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Sunday. Zacks Investment Research downgraded Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th. HC Wainwright restated a “neutral” rating and set a $150.00 price target (up from $144.00) on shares of Jazz Pharmaceuticals in a report on Friday, November 10th. UBS reduced their price target on Jazz Pharmaceuticals from $172.00 to $168.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $172.00 price target (down from $177.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $181.28.

Jazz Pharmaceuticals (JAZZ) opened at $133.66 on Tuesday. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $8,186.84, a price-to-earnings ratio of 17.13, a price-to-earnings-growth ratio of 0.88 and a beta of 0.98. Jazz Pharmaceuticals has a twelve month low of $99.28 and a twelve month high of $163.75.

In related news, Director Patrick G. Enright sold 352 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the sale, the director now directly owns 1,365 shares in the company, valued at approximately $181,804.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Iain Mcgill sold 8,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.42, for a total value of $1,067,360.00. Following the completion of the sale, the senior vice president now owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The disclosure for this sale can be found here. Insiders sold a total of 10,352 shares of company stock valued at $1,417,763 over the last quarter. 4.30% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Toronto Dominion Bank boosted its position in Jazz Pharmaceuticals by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 81 shares during the last quarter. US Bancorp DE boosted its position in Jazz Pharmaceuticals by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 368 shares during the last quarter. Gargoyle Investment Advisor L.L.C. purchased a new position in Jazz Pharmaceuticals in the second quarter worth about $206,000. Advisor Group Inc. boosted its position in Jazz Pharmaceuticals by 62.4% in the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after purchasing an additional 550 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in Jazz Pharmaceuticals in the second quarter worth about $211,000. 91.30% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Mizuho Increases Jazz Pharmaceuticals (JAZZ) Price Target to $150.00” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/07/mizuho-increases-jazz-pharmaceuticals-jazz-price-target-to-150-00.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.